Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
Top Cited Papers
Open Access
- 1 September 2015
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 68 (3) , 386-396
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Androgen Deprivation Therapy and Cardiovascular RiskJournal of Clinical Oncology, 2011
- The Levels of Evidence and Their Role in Evidence-Based MedicinePlastic and Reconstructive Surgery, 2011
- The Heart: A Novel Gonadotrophin-Releasing Hormone TargetJournal of Neuroendocrinology, 2011
- Bias Formulas for Sensitivity Analysis of Unmeasured Confounding for General Outcomes, Treatments, and ConfoundersEpidemiology, 2011
- Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe SwedenThe Lancet Oncology, 2010
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate CancerJNCI: Journal of the National Cancer Institute, 2009
- Molecular and cellular mechanisms of the thrombotic complications of atherosclerosisJournal of Lipid Research, 2009
- Cardiovascular Mortality After Androgen Deprivation Therapy for Locally Advanced Prostate Cancer: RTOG 85-31Journal of Clinical Oncology, 2009
- Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetryJournal of Clinical Epidemiology, 2008
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006